share_log

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K:Vivos Therapeutics公佈2024年第二季度財務業績並提供最新運營情況
美股SEC公告 ·  08/15 12:57
Moomoo AI 已提取核心訊息
On August 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the second quarter ended June 30, 2024. The company reported a 19% increase in revenue to $4.1 million for the quarter and $7.5 million for the first half of the year. This growth is attributed to higher product sales and service revenue, including an increase in Vivos Integrated Provider enrollment revenue. Gross profit also rose to $2.7 million for the quarter, with a gross margin increase to 65%. Operating expenses decreased by 31% due to successful cost-cutting initiatives, leading to a significant reduction in operating loss. Vivos also highlighted its strategic marketing and distribution alliance with a Colorado sleep treatment operator and a...Show More
On August 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the second quarter ended June 30, 2024. The company reported a 19% increase in revenue to $4.1 million for the quarter and $7.5 million for the first half of the year. This growth is attributed to higher product sales and service revenue, including an increase in Vivos Integrated Provider enrollment revenue. Gross profit also rose to $2.7 million for the quarter, with a gross margin increase to 65%. Operating expenses decreased by 31% due to successful cost-cutting initiatives, leading to a significant reduction in operating loss. Vivos also highlighted its strategic marketing and distribution alliance with a Colorado sleep treatment operator and a $7.5 million equity investment from New Seneca Partners, Inc. The company anticipates positive cash flow in early 2025 and has treated over 45,000 patients with its patented oral appliances. Additionally, Vivos received regulatory approvals for Medicare reimbursement for its CARE oral devices and announced positive results from a marketing pilot for its oral appliance therapy.
2024年8月14日,專注於治療睡眠呼吸障礙的醫療器械和科技公司Vivos Therapeutics宣佈截至2024年6月30日第二季度的財務業績。公司報告本季度營業收入增長19%,達到了410萬元人民幣,上半年收入達到了750萬元人民幣。這一增長歸因於更高的產品銷售和服務收入,包括Vivos Integrated Provider計劃收入的增加。本季度毛利潤也增長到了270萬元人民幣,毛利率提高到了65%。由於成功的成本削減舉措,營業費用減少了31%,從而使營業虧損大大降低。Vivos還強調了與科羅拉多州的一個睡眠治療運營商的戰略營銷和分銷聯盟以及新塞內卡合夥公司的750萬元人民幣股權投資。該公司預計在2025年初實現正現金流,並已爲其專利口腔裝置治療了超過45,000名患者。此外,Vivos還獲得了CARE口腔裝置在醫療保險報銷方面的監管批准,並宣佈其口腔裝置治療的營銷試點獲得了積極的效果。
2024年8月14日,專注於治療睡眠呼吸障礙的醫療器械和科技公司Vivos Therapeutics宣佈截至2024年6月30日第二季度的財務業績。公司報告本季度營業收入增長19%,達到了410萬元人民幣,上半年收入達到了750萬元人民幣。這一增長歸因於更高的產品銷售和服務收入,包括Vivos Integrated Provider計劃收入的增加。本季度毛利潤也增長到了270萬元人民幣,毛利率提高到了65%。由於成功的成本削減舉措,營業費用減少了31%,從而使營業虧損大大降低。Vivos還強調了與科羅拉多州的一個睡眠治療運營商的戰略營銷和分銷聯盟以及新塞內卡合夥公司的750萬元人民幣股權投資。該公司預計在2025年初實現正現金流,並已爲其專利口腔裝置治療了超過45,000名患者。此外,Vivos還獲得了CARE口腔裝置在醫療保險報銷方面的監管批准,並宣佈其口腔裝置治療的營銷試點獲得了積極的效果。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息